What's Happening?
A study published in The Lancet Psychiatry has found that antipsychotic drugs are frequently prescribed to dementia patients outside of NICE guidelines. The research analyzed data from 9,819 dementia patients who received their first antipsychotic prescription between 2000 and 2023. It revealed that 18.1% of patients were started on doses above the minimum effective level, and the median duration of initial treatment was seven months, exceeding the recommended one to three months. The study highlights concerns about the prolonged and high-dose use of antipsychotics, which can lead to avoidable harms such as mortality, stroke, and pneumonia.
Why It's Important?
The findings underscore the need for improved prescribing practices and oversight in dementia care. Despite efforts to reduce antipsychotic use following the Banerjee report, which estimated 1,800 additional deaths annually due to these drugs, the study indicates persistent issues. The results call for stronger systems to support safer prescribing, including regular medication reviews and investment in psychosocial interventions. Pharmacy staff play a crucial role in ensuring appropriate use and adopting a holistic approach to medication reviews, which could mitigate risks associated with antipsychotic and similar medications.
Beyond the Headlines
The study raises ethical concerns about the reliance on antipsychotics as first-line treatments, often ahead of non-drug therapies. It suggests a need for a shift in focus from managing behavior to considering the individual's lifelong patterns and wellbeing. The importance of psychosocial interventions is emphasized, advocating for their integration into dementia care plans. This approach could reduce medication dependency and enhance the quality of life for dementia patients.
